Ergot Alkaloid Pharmacology

Hyperprolactinemia — elevated serum prolactin — presents clinically as galactorrhea (inappropriate milk production), amenorrhea, and infertility in women, and as hypogonadism and sexual dysfunction in men. The most common causes are prolactin-secreting pituitary adenomas and medications that block dopamine receptors (antipsychotic drugs, metoclopramide). Bromocriptine is first-line pharmacological therapy for symptomatic hyperprolactinemia from any cause.

At standard doses, bromocriptine normalizes serum prolactin, restores menstrual cycles, and resolves galactorrhea in most patients. In patients with a prolactin-secreting pituitary adenoma (prolactinoma), bromocriptine not only suppresses prolactin secretion but also shrinks the tumor itself in many cases — a property that distinguishes dopamine agonist therapy from most endocrine tumor treatments. Tumor shrinkage occurs because dopamine type 2 receptor activation inhibits both the secretory and proliferative functions of lactotroph cells.

In Parkinson’s disease, degeneration of dopaminergic neurons in the substantia nigra depletes dopamine signaling in the striatum, producing the characteristic motor features of the disease. Bromocriptine acts as a dopamine agonist in the basal ganglia, directly stimulating dopamine type 2 receptors on striatal neurons and partially compensating for the loss of endogenous dopamine. It is used as an adjunct to levodopa therapy in patients whose motor control is not adequately managed by levodopa alone, and as an early monotherapy in patients for whom levodopa initiation is being delayed.

Bromocriptine is less effective in Parkinson’s disease than the newer, more selective dopamine agonists such as pramipexole and ropinirole, which have largely replaced it in this indication. Its use in Parkinson’s disease is now relatively uncommon in current clinical practice, though it remains a tested concept at the second-year level.

In acromegaly — growth hormone excess from a pituitary somatotroph adenoma — bromocriptine reduces growth hormone secretion through dopamine type 2 receptor agonism on somatotroph cells. This effect is paradoxical in the context of normal physiology, where dopamine stimulates growth hormone release, but in somatotroph adenoma cells the receptor pharmacology is reversed. Bromocriptine is considerably less effective for acromegaly than somatostatin analogs such as octreotide and is used only when those agents are not tolerated or are unavailable.

A cycloset formulation of bromocriptine is approved for type 2 diabetes management. The mechanism in this context relates to resetting circadian dopamine rhythms in the hypothalamus to improve insulin sensitivity, but this indication is less well understood mechanistically and is not a high-yield Step 1 concept compared to the hyperprolactinemia and Parkinson’s disease indications.

Nausea and vomiting are the most common adverse effects of bromocriptine and result from dopamine type 2 receptor activation in the chemoreceptor trigger zone of the medulla — the same zone that detects emetic stimuli. Starting at low doses and titrating slowly reduces but does not eliminate this problem. Orthostatic hypotension occurs because dopamine type 2 receptor activation in the cardiovascular system reduces sympathetic tone, leading to a drop in blood pressure upon standing.

At the higher doses used in Parkinson’s disease, bromocriptine can produce dyskinesias — involuntary movements that resemble those caused by levodopa excess — as well as psychiatric effects including hallucinations and confusion. These neuropsychiatric effects reflect excessive dopaminergic stimulation in limbic circuits and are the primary dose-limiting adverse effects in Parkinson’s disease management. Patients with dementia are particularly vulnerable and may experience severe psychiatric symptoms at doses that are well tolerated in cognitively intact patients.

Dopaminergic ergot alkaloids — bromocriptine, cabergoline, and the now-withdrawn pergolide — share a class risk of cardiac valve fibrosis that is not present with non-ergot dopamine agonists such as pramipexole or ropinirole. The mechanism involves serotonin type 2B receptor agonism on cardiac valve interstitial cells, stimulating fibroblast proliferation and collagen deposition that thickens and stiffens the valve leaflets.

This risk is dose-dependent and is most clinically significant with cabergoline used at the high doses required for Parkinson’s disease — doses substantially higher than those used for hyperprolactinemia. At hyperprolactinemia doses, the cardiac risk is considered low and routine echocardiographic monitoring is generally not required. At Parkinson’s disease doses, periodic echocardiography is recommended to detect early valve changes before they become symptomatic. Pergolide was withdrawn from the United States market in 2007 specifically because of this valvulopathy risk, which was judged unacceptable given the availability of safer alternatives.

Cabergoline has largely replaced bromocriptine as the preferred dopaminergic ergot for hyperprolactinemia. It has a much longer half-life than bromocriptine — allowing twice-weekly rather than daily dosing — and is better tolerated, with significantly less nausea and orthostatic hypotension at the doses used for prolactin suppression. Efficacy for prolactinoma shrinkage is comparable or superior. The cardiac valvulopathy risk at hyperprolactinemia doses is low for both agents, but cabergoline’s tolerability advantage has made it the clinical standard in most settings.